The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...
The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...
Migraine may be a symptom of prodromal multiple sclerosis (MS), as the risk for migraine gradually increased closer to the ...
GlobalData on MSN14h
FDA adds boxed warning to multiple sclerosis drugs after anaphylaxis casesTeva Pharmaceutical’s Copaxone was approved by the FDA in 1996 to treat relapsing forms of MS, an autoimmune disorder that ...
People with multiple sclerosis (MS) face a significantly higher risk of perinatal mental illness compared to those with other ...
After years of legal wrangling surrounding Teva’s Copaxone, the latest hit to the lucrative multiple sclerosis drug comes in ...
The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.
Overall, women with MS have a 26% increased risk of mental illness during pregnancy and a 33% increased risk after giving birth, compared to women without the degenerative nerve disease.
Mothers with multiple sclerosis (MS) have an elevated incidence and prevalence of peripartum mental illness, accordi ...
A new study reveals that people with multiple sclerosis (MS) experience significantly higher rates of mental illness during ...
The drugs’ active ingredient, glatiramer acetate, has been linked to more than 80 cases of anaphylaxis worldwide since ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback